Board summary
Key figures
34,496
Registered population
56.4% aged 18–64
23.7%
Aged 65+
ICB 18.8% · England 17.9%
6.8%
Ethnic minority (non-White)
2.4% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
5,596
Hypertension register
+11.76% in 3 yrs · England +5.60%
226
SMI register
24.6% of Tandridge's
578
COPD register
Reviews +1.14% in 3 yrs
Forecast to 2030
7,441
Hypertension patients, 2049
+1,845 on today
66.1%
QRISK ≥20% on statins, 2049
+2.54pp over 3 yrs
7.3%
Cancer prevalence, 2049
England 4.5%
Three things the board should see
Under-80 blood pressure control fell over three years.
Control in under-80s sits at 65.3% (England 67.8%) after a -6.4% change over 2023 to 2025 against +3.2% in England.
Annual asthma reviews trail local and national benchmarks.
Only 59.3% had a review (Tandridge 66.4%, ICB 65.6%, England 65.7%), leaving about 850 of 2,096 asthma patients unreviewed after a -5.1% three-year change.
Non-frail diabetes HbA1c control outpaced comparator growth.
HbA1c control at or below 58 mmol/mol rose +11.2% over 2023 to 2025 (Tandridge +4.0%, ICB +3.6%, England +4.4%), reaching 55.6% against 57.4% nationally.
Population, age and ethnicity
Older patients comprise 23.7% of the list alongside 17 catchment care homes
Across 34,496 registered patients, 23.7% (8,161) are aged 65+, above Tandridge (20.9%), the ICB (18.8%) and England (17.9%). Working-age adults (18–64) represent 56.4% and children (0–17) 19.9%. Census resident data shows 93.2% White background (Tandridge 89.4%, ICB 85.3%, England 81.1%), alongside 2.4% Asian and 1.1% Black residents. Unverified ONS projections model +5.6% list growth to 2030 (Tandridge +6.0%, ICB +4.9%, England +2.3%). Registered lists and Census resident catchments have different population bases.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Tandridge local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Tandridge LA) | 2,455 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.6% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Tandridge LA) | 1,233 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Tandridge LA) | 12.0 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share is 0.0% across all practices, with average IMD decile 6.8
No registered patients (0.0%, 0 estimated patients) live in Core20 areas (the most deprived 20% of areas nationally), matching Tandridge (0.0%), below NHS Surrey Heartlands Integrated Care Board (0.8%), and 21.0 percentage points below England (21.0%). Average IMD decile is 6.8 (Tandridge 7.1, ICB 7.9, England 5.5). By practice, Core20 share is 0.0% across Pond Tail Surgery (IMD decile 5.3), Lingfield Surgery (decile 6.6), and Oxted Health Centre (decile 8.0). With 0.0% Core20 reach, tackling local inequalities requires prioritising inclusion health cohorts over area-based outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
226
SMI register
0.65% recorded prevalence
274
Learning disability register
0.79% recorded prevalence
17
Care homes, 572 beds
In the PCN catchment
8.3%
Provide unpaid care
Tandridge, Census 2021
The PCN records 274 learning disability patients (0.8%; Tandridge 0.7%, ICB 0.5%, England 0.6%) and 226 severe mental illness patients (0.7%; Tandridge 0.8%, ICB 0.8%, England 1.0%), alongside 17 catchment care homes (572 beds). Gypsy or Irish Traveller residents comprise 0.6% (England 0.1%). Sites and bed capacity do not establish occupancy or registered care-home residents.
Severe mental illness: physical health checks
Across 226 severe mental illness patients, annual blood pressure checks reached 78.9% (England 83.4%) and BMI checks reached 78.3% (England 82.1%). Gaps may reflect recall barriers, which dedicated outreach review would test.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,596
Hypertension register
+11.76%
Register growth, 3 yrs
Tandridge +6.34% · England +5.60%
−4.44pp
BP control, under 80
≤140/90 · +0.20pp aged 80+
+1,845
More patients by 2030
Forecast 7,441 (20.06%)
Hypertension case-finding and control
Hypertension register prevalence is 16.1% (5,596 patients), above England (15.2%), Tandridge (15.3%) and NHS Surrey Heartlands Integrated Care Board (14.3%), having expanded +11.8% over 2023 to 2025 (England +5.6%). However, recent blood pressure recording fell 2.9% over 2023 to 2025 (England +3.6%) to 85.3% (England 90.0%). Blood pressure control in patients aged under 80 dropped 6.4% over 2023 to 2025 (England +3.2%) to 65.3% (England 67.8%), spanning from 61.8% at Pond Tail Surgery and 63.8% at Oxted Health Centre to 70.0% at Lingfield Surgery. Control for ages 80+ is 75.3% (England 81.2%). Declining control could reflect routine recall capacity lagging register growth, which a clinical capacity audit would test.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy uptake is 60.7%, below England (63.6%) but above Tandridge (58.5%). Uptake among CKD patients is 62.9% (England 70.3%). Lower uptake than England may indicate treatment gaps, which a targeted prescribing review would test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 43,656 | £2.70 | £2.24 | £1.86 | £117,871 |
| Cardiovascular (all), 2025 | 63,400 | £4.82 | £4.74 | £3.33 | £305,588 |
In 2026, 43,656 lipid-regulating items were prescribed at £2.70 per item, above England (£1.86), Tandridge (£2.36) and NHS Surrey Heartlands Integrated Care Board (£2.24). This unit-cost difference represents £36,671 more than at England's unit cost across 43,656 items. Higher unit costs could reflect product choice rather than prescribing inefficiency, which a formulary audit would test.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−5.07%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.04%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.4% (2,096 patients). Over 2023 to 2025, annual asthma reviews fell 5.1% (England +4.4%) to 59.3% (England 65.7%, Tandridge 66.4%, ICB 65.6%), leaving about 850 patients unreviewed, ranging from 51.9% at Oxted Health Centre to 70.3% at Lingfield Surgery. Second-hand smoke recording for ages 6–19 is 67.8% (England 78.8%). COPD prevalence is 1.7% (England 1.9%), and COPD reviews reached 71.6% (England 76.4%). Review shortfalls could reflect recall capacity constraints, which an appointment audit would test.
Cancer register and children's immunisation
The cancer register comprises 2,051 patients (5.9% prevalence vs England 3.8%). For childhood immunisations, 6-in-1 coverage at 12 months reaches 97.4% and MMR dose 1 at age 5 reaches 95.6% (meeting the 95.0% target). However, MMR dose 2 coverage at age 5 is 85.7%, reflecting a 9.9 pp difference between first and second dose across South Tandridge PCN.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, 61.4% of staged cancers across NHS Surrey Heartlands ICB were diagnosed at stage 1 or 2 (2,955 of 4,810 known-stage cases), above England (55.3%) but below the 75.0% national ambition by 13.6 pp. Known staging covered 67.7% of registered cancers (4,810 of 7,106). Closing this gap requires about 650 extra early-stage diagnoses yearly system-wide. Locally, PCN cancer prevalence is 5.9% (2,051 patients), rising +11.5% over 2023 to 2025 (England +9.0%). Cervical screening uptake is 75.7% (England 66.8%), but fell 2.3% over 2023 to 2025 (England -1.0%). ICB staging reflects wider system patterns, not PCN performance. Sustaining early detection requires protecting routine screening uptake as register prevalence expands.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional) at Surrey and Sussex Healthcare NHS Trust, cancer 62-day referral to treatment was 70.0% against the 85.0% standard (NHS Surrey and Sussex ICB 71.5%, England 71.2%), with King's College Hospital NHS Foundation Trust at 70.1% and Croydon Health Services NHS Trust at 69.9%. The trust achieved the 28-day faster diagnosis standard at 77.7% (standard 75.0%; ICB 79.3%, England 79.3%) and the 31-day standard at 96.2%. Diagnostic waits show 28.5% waiting 6+ weeks (England 23.1%), including 32.3% for non-obstetric ultrasound. Provider performance reflects acute capacity, not PCN delivery.
| Pathways within standard (%) | Surrey and Sussex Healthcare | King's College | Croydon Health | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 80.68 | 83.22 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 96.68 | 99.06 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 70.15 | 69.88 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | King's College | Croydon Health | England |
|---|---|---|---|---|
| MRI | 27.53 | 21.22 | 0.26 | 21.40 |
| CT | 18.49 | 22.60 | 7.69 | 9.92 |
| Echocardiography | 43.78 | 14.39 | 3.60 | 28.48 |
| Colonoscopy | 15.11 | 41.81 | 21.80 | 30.83 |
| Gastroscopy | 21.06 | 35.98 | 17.94 | 29.02 |
| All 15 DM01 tests | 28.50 | 19.15 | 3.51 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In Jun 2026 (provisional), 33,510 Surrey residents had a community care contact, generating 109,530 contacts and 66,060 care activities. Adults aged 65+ accounted for 69.6% of these contacts. Across NHS Surrey and Sussex Integrated Care Board, 309,615 care contacts and 316,320 activities were recorded. These provisional experimental figures describe submitting providers rather than South Tandridge PCN activity.
Practice variation and patient experience
Easy phone access spans 31.6 percentage points across the three member practices
In 2025/26, overall QOF achievement was 100.0% at Lingfield Surgery, 98.0% at Pond Tail Surgery, and 95.3% at Oxted Health Centre, compared with 92.5% across England. Vaccination and immunisation achievement spanned 35.6 percentage points, from 64.4% at Oxted Health Centre to 100.0% at Lingfield Surgery. At Lingfield Surgery, the vaccination and immunisation domain personalised care adjustment rate was 15.4%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Pond Tail Surgery | 105 | 0.0 | 73.5% | 66.8% | 91.7% |
| Oxted | 112 | 0.0 | 41.9% | 61.6% | 68.3% |
| Lingfield Surgery | 135 | 0.0 | 45.8% | 71.5% | 67.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Thirteen of 25 tracked measures trailed England over three years, led by hypertension
Across 25 tracked measures, 13 trailed England's three-year change (2023 to 2025). Relative lags were widest in under-80 hypertension blood pressure control, which fell 6.4% (England +3.2%), and asthma reviews, which fell 5.1% (England +4.4%). Heart failure reviews rose +3.3% (England +8.7%). Conversely, diabetes HbA1c control without frailty rose +11.2% (England +4.4%), secondary CVD diabetic statin therapy rose +4.5% (England +1.0%), and breast screening rose +11.2% (England +8.4% over 2023 to 2024). This diverging pattern could reflect routine recall capacity pressures rather than broad clinical decline, though this has not been confirmed locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BP control, under 80
Asthma reviews
Hypertension treated to target
Hypertension BP reading
Heart failure reviews
Diabetes HbA1c control
Diabetes statin (CVD)
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Tandridge | Asset | PCN | Tandridge |
|---|---|---|---|---|---|
| Care homes (catchment) | 17 (572 beds) | n/a | Schools (catchment) | 45 | n/a |
| Children's centres | 2 | 6 | Places of worship | 35 | 61 |
| Libraries | 2 | 4 | Food banks (VCS) | n/a | 2 |
| Homelessness support (VCS) | 0 | no data | Day centres (VCS) | 4 | 5 |
| Children and young people (VCS) | 1 | 1 | Carers support groups (VCS) | 3 | 3 |
| Primary schools (LA maintained) | 9 | 14 | Primary academies | 5 | 11 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension recall and BP control
Hypertension grew +11.8% over 2023 to 2025 to 5,596 patients (16.1%), while under-80 BP control fell 6.4% (England +3.2%) to 65.3% (England 67.8%, ICB 68.1%, Tandridge 67.7%), and recent BP recording fell 2.9% to 85.3%. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Annual asthma review recall capacity
Asthma annual reviews fell 5.1% over 2023 to 2025 (England +4.4%) to 59.3% across the 2,096-patient register (England 65.7%, Tandridge 66.4%, ICB 65.6%), leaving about 850 patients without a recorded review. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Pre-school MMR2 and booster recall
In Q1 2025/26 (cohort 91), age-5 MMR1 coverage reached 95.6% (above the 95.0% target), but MMR2 was 85.7% (below target by 9.3 pp; 9.9 pp dose difference) and 4-in-1 booster was 84.6%. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Frailty and older age planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| SMI physical health outreach (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall alignment (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension recall and BP control (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Annual asthma review recall capacity (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 3 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
